RecruitingPHASE2, PHASE3NCT07204275
A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
Studying Primary membranous glomerulonephritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Intervention
- Povetacicept(drug)
- Enrollment
- 176 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2025 – 2028
Study locations (30)
- Renal Associates, Montgomery, Alabama, United States
- Southwest Kidney Institute, PLC (SKI) - Surprise, Surprise, Arizona, United States
- Academic Medical Research Institute (AMRI), Los Angeles, California, United States
- Valiance Clinical Research - Internal Medicine, Tarzana, California, United States
- Western Nephrology & Metabolic Bone Disease PC, Arvada, Colorado, United States
- Bioresearch Partner, Miami, Florida, United States
- CTR Oakwater, LLC, Orlando, Florida, United States
- Clinical Site Partners, LLC - Orlando, Winter Park, Florida, United States
- DaVita Clinical Research Columbus, Columbus, Georgia, United States
- Georgia Nephrology, Lawrenceville, Georgia, United States
- CARE Institute-Boise Kidney, Boise, Idaho, United States
- NANI Research, Hinsdale, Illinois, United States
- DaVita Clinical Research Edina, Edina, Minnesota, United States
- Kidney Specialists of Southern Nevada, Las Vegas, Nevada, United States
- Carolina Nephrology Greenville, Greenville, South Carolina, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Zai Lab (Shanghai) Co., Ltd. (for China only)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07204275 on ClinicalTrials.govOther trials for Primary membranous glomerulonephritis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07289763Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous NephropathyGuangdong Hengrui Pharmaceutical Co., Ltd
- RECRUITINGPHASE2NCT07157787Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)Alexion Pharmaceuticals, Inc.
- RECRUITINGPHASE2NCT07096843A Phase 2 Study of Budoprutug in Subjects With Primary Membranous NephropathyClimb Bio, Inc.
- RECRUITINGPHASE3NCT06962800A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)Biogen
- RECRUITINGPHASE1NCT06982729Study of YK012 in Primary Membranous NephropathyExcyte Biopharma Ltd
- RECRUITINGNCT06242327An Outcome Analysis of Primary Membranous NephropathyMario Negri Institute for Pharmacological Research
- ACTIVE NOT RECRUITINGPHASE2NCT06642909A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous NephropathyBioRay Pharmaceutical Co., Ltd.
- RECRUITINGNCT06893328A Real World Study About PMNWei Chen